Investigating how SARM1 contributes to nerve damage and inflammation
The role of SARM1 in neuroinflammation-mediated axonal damage
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-11072013
This study is looking at a protein called SARM1 that affects nerve health in people with ALS, and it aims to find ways to stop the damage it causes so that those with ALS can keep their motor skills longer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11072013 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of SARM1, a protein involved in nerve cell health, particularly in conditions like amyotrophic lateral sclerosis (ALS). It explores how SARM1 activation leads to nerve damage through inflammation and the recruitment of immune cells called macrophages. By developing a human disease model, the research aims to identify ways to block harmful processes initiated by SARM1, potentially improving motor function in affected individuals. The approach includes manipulating signals that attract macrophages to damaged nerves, which could delay nerve degeneration.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with amyotrophic lateral sclerosis or related neurodegenerative diseases characterized by axonal damage.
Not a fit: Patients with conditions unrelated to axonal degeneration or those not experiencing neuroinflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or prevent nerve damage in patients with ALS and similar conditions.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways for neuroprotection, indicating potential for success in this novel approach.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MILBRANDT, JEFFREY D — WASHINGTON UNIVERSITY
- Study coordinator: MILBRANDT, JEFFREY D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Amyotrophic Lateral Sclerosis Motor Neuron Disease